Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
NextCure Inc
NXTC | US
3.40
USD0.02
0.59%
NXTC | US
About NextCure Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
02/06/2026
Close
3.40
Open
3.65
High
3.66
Low
3.32
NextCure Inc. a clinical-stage biopharmaceutical company engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410 an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762 a monoclonal antibody that binds specifically to B7-H4 a protein expressed on multiple tumor types; and NC525 a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. The company has a license agreement with Yale University. NextCure Inc. was incorporated in 2015 and is headquartered in Beltsville Maryland.
View LessNXTC | US
Risk
197.3
Sharpe
-0.40
Luna's Score
49/100
Recommendation
Hold
Luna says (NXTC | US)
What's Working
Strength based on increasing price with high volume
High Current Volume and Positive 1-Day Return
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
What's not Working
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
257.7%1 month
197.3%3 months
136.5%6 months
108.5%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
0.45
Debt to equity
0.07
Debt to assets
0.06
Ent. to EBITDA
0.51
Ent. to rev.
1.62
PEG
-
Other Fundamentals
EBITDA
-60.40M
MarketCap
95.12M
MarketCap(USD)
95.12M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-100.00
Ret. on equity
-54.75
Short ratio
1.87
Short perc.
0.29
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
7.87
Range1M
8.29
Range3M
11.52
Volumes: Market Activity
Rel. volume
2.69
Price X volume
807.45K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.51 | - | Par |
| Ent. to Revenue | 1.62 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 0.45 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 136.46 | - | Riskier |
| Debt to Equity | 0.07 | -1.23 | Expensive |
| Debt to Assets | 0.06 | 0.25 | Cheaper |
| Market Cap | 95.12M | - | Emerging |
